Drug intelligence / Profile preview

microRNA-548aq-3p mimic

Development stage
Preclinical
Modality
MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01

Overview

microRNA-548aq-3p mimic is a synthetic double-stranded RNA oligonucleotide designed to simulate the biological activity of the endogenous mature microRNA, miR-548aq-3p. In the context of oncology research, specifically epithelial ovarian cancer, this mimic is used to investigate the mechanisms of chemotherapy resistance. It functions by post-transcriptionally downregulating the expression of the RNA polymerase II mediator complex subunit 12 (MED12). Research indicates that the overexpression of miR-548aq-3p via these mimics enhances cell survival and proliferation while conferring resistance to cisplatin treatment. While the mimic itself is primarily utilized as a research tool to characterize disease progression and drug resistance, the miR-548aq-3p/MED12 signaling axis is considered a significant therapeutic target for the development of miRNA inhibitors (antagomirs) to restore chemotherapy sensitivity.

Other names
miR-548aq-3p mimicmiR548aq-3p mimicmiR 548aq-3p mimichsa-miR-548aq-3p mimichsa-miR548aq-3p mimichsa-miR 548aq-3p mimicmicroRNA-548aq mimicmicroRNA548aq mimicmicroRNA 548aq mimic
02

Targets

OPA1 (OPA1 mitochondrial dynamin-like GTPase)

Beyond the preview

Go deeper on microRNA-548aq-3p mimic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on microRNA-548aq-3p mimic.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call